Bank Of New York Mellon Corp Olema Pharmaceuticals, Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$2.27 - $3.76 $27,694 - $45,872	12,200 New	12,200 $29,000
Q3 2022 Nov 14, 2022	SELL	$2.72 - $5.88 $231 - $499	-85 Reduced 0.69%	12,200 $34,000
Q2 2022 Aug 15, 2022	SELL	$2.04 - $4.61 $153,163 - $346,118	-75,080 Reduced 85.94%	12,285 $50,000
Q1 2022 May 11, 2022	SELL	$3.89 - $9.43 $4,092 - $9,920	-1,052 Reduced 1.19%	87,365 $372,000
Q4 2021 Feb 11, 2022	BUY	$8.75 - $30.71 $59,333 - $208,244	6,781 Added 8.31%	88,417 $828,000
Q3 2021 Nov 12, 2021	BUY	$22.96 - $30.13 $1.07 Million - $1.41 Million	46,653 Added 133.36%	81,636 $2.25 Million
Q2 2021 Aug 11, 2021	BUY	$21.15 - $36.14 $62,455 - $106,721	2,953 Added 9.22%	34,983 $978,000
Q1 2021 May 13, 2021	BUY	$27.81 - $53.64 $890,754 - $1.72 Million	32,030 New	32,030 $1.06 Million

145

58.3M

141K

23.1K

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $248M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.